Silexion Therapeutics (NASDAQ:SLXN) reported quarterly losses of $(1.40) per share which missed the analyst consensus estimate of $(1.07) by 30.84 percent. This is a 100.66 percent decrease over earnings of $213.60 per share from the same period last year.